AgingResearch.NewsJoin free

Renin-angiotensin system inhibitor

Renin-angiotensin system inhibitor has been studied in 3 papers since 2020: 3 observational studies in people; 2 in the past year. The newest story, Oct 26, 2026: “Four heart failure drugs linked to fewer deaths in older adults”.

Intervention

3 papers study it5 findingsUpdated

1 new paper in 30 daysSee all 3 papers on renin-angiotensin system inhibitor

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Multivariable logistic regression analyses revealed that AMD prevalence had no significant association with RASI usage”
Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008Journal of ophthalmology2020doi:10.1155/2020/4252031

1 of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Against: findings that point the other way from most findings on the same outcome.

  • 1 lab in 1 country
  • 1 finding against
  • Funders: Government of Jiangsu Province and 3 more
  • Humans3

What did studies of renin-angiotensin system inhibitor find?

1

Studies of renin-angiotensin system inhibitor measured one outcome, age-related macular degeneration.

Age-related macular degeneration

no changein humans1

1 study

  1. Renin-angiotensin system inhibitor was not clearly linked with age-related macular degeneration in humans (RASI usage overall, in hypertensive participants).

    “Multivariable logistic regression analyses revealed that AMD prevalence had no significant association with RASI usage”

    HumansRASI usage overall, in hypertensive participants

    Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008

    Journal of ophthalmology

More on Age-related macular degeneration

What is renin-angiotensin system inhibitor linked with?

3

Studies link renin-angiotensin system inhibitor with 3 measures: age-related macular degeneration, geographic atrophy and soft drusen.

Age-related macular degeneration

downin humans1OR 0.23–0.87

1 study

  1. Renin-angiotensin system inhibitor is linked with a lower risk of age-related macular degeneration in humans (long-term use for more than 5 years, in hypertensive participants) (OR 0.23 (95% CI 0.14-0.38)).

    “Long-term usage (>5 years) of RASIs was significantly associated with not only reduced overall risk of AMD (OR = 0.23, 95% CI = 0.14-0.38, p < 0.001)”

    Humanslong-term use for more than 5 years, in hypertensive participantsmore than 5 years

    Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008

    Journal of ophthalmology

  2. Renin-angiotensin system inhibitor is associated with age-related macular degeneration in humans (by RASI treatment duration, in hypertensive participants) (OR 0.87 (95% CI 0.78-0.98)).

    “but was inversely correlated with RASI treatment duration (odds ratio (OR) = 0.87, 95% confidence interval (CI) = 0.78-0.98, p=0.02)”

    Humansby RASI treatment duration, in hypertensive participants

    Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008

    Journal of ophthalmology

More on Age-related macular degeneration

Geographic atrophy

downin humans1OR 0.39

1 study

  1. Renin-angiotensin system inhibitor is linked with a lower risk of geographic atrophy in humans (long-term use, in hypertensive participants) (OR 0.39 (95% CI 0.22-0.71)).

    “and geographic atrophy (GA) (OR = 0.39, 95% CI = 0.22-0.71, p=0.003)”

    Humanslong-term use, in hypertensive participantsretinamore than 5 years

    Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008

    Journal of ophthalmology

More on Geographic atrophy

Soft drusen

downin humans1OR 0.67

1 study

  1. Renin-angiotensin system inhibitor is linked with a lower risk of soft drusen in humans (long-term use, in hypertensive participants) (OR 0.67 (95% CI 0.45-0.99)).

    “long-term RASI users were less prone to develop soft drusen (OR = 0.67, 95% CI = 0.45-0.99, p=0.04)”

    Humanslong-term use, in hypertensive participantsretinamore than 5 years

    Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008

    Journal of ophthalmology

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 02 papers in 12 months
ESC Congress 2026 Abstract

Four heart failure drugs linked to fewer deaths in older adults

Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.

Cohort · 1,868 peoplePopulations
Paper

Related